PMCB
PharmaCyte Biotech, Inc. Common Stock
stockNASDAQ
pharmacyte biotech, inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the united states. its cellular therapies are developed based on cell-in-a-box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. the company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. it is also developing a therapy for type 1 diabetes and insulin-dependent type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. pharmacyte biotech, inc. has a research agreement with the university of technology, sydney to create a version of melligen cells to treat diabetes; and a research agreeme
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.42 | 2026-09-28 | -4.71% | 0.166 |
| 1M | 0.49 | 2026-09-04 | -17.76% | 1.653 |
| 3M | 0.73 | 2026-07-06 | -45.19% | 1.818 |
| 6M | 0.71 | 2026-04-06 | -43.42% | 1.734 |
| 1Y | 1.04 | 2025-10-03 | -61.53% | 1.662 |
| 2Y | 1.77 | 2024-10-04 | -77.39% | — |
| 5Y | 3.05 | 2021-10-04 | -86.88% | 0.676 |
PharmaCyte Biotech, Inc. Common Stock (NASDAQ:PMCB) stock price today is $0.40, and today's volume is 44,652. PMCB is down 0.941% today. The 30 day average volume is 298,250. PMCB market cap is $4.30M with 10.74M shares outstanding.